MX2022005029A - Metodos de tratamiento y/o prevencion de acontecimientos cardiovasculares adversos graves (mace) con una combinacion de un inhibidor de bromodominio y extraterminal (bet) y un inhibidor de transporte de glucosa dependiente de sodio 2. - Google Patents

Metodos de tratamiento y/o prevencion de acontecimientos cardiovasculares adversos graves (mace) con una combinacion de un inhibidor de bromodominio y extraterminal (bet) y un inhibidor de transporte de glucosa dependiente de sodio 2.

Info

Publication number
MX2022005029A
MX2022005029A MX2022005029A MX2022005029A MX2022005029A MX 2022005029 A MX2022005029 A MX 2022005029A MX 2022005029 A MX2022005029 A MX 2022005029A MX 2022005029 A MX2022005029 A MX 2022005029A MX 2022005029 A MX2022005029 A MX 2022005029A
Authority
MX
Mexico
Prior art keywords
inhibitor
mace
sodium
methods
combination
Prior art date
Application number
MX2022005029A
Other languages
English (en)
Spanish (es)
Inventor
Kenneth Eugene Lebioda
Christopher Ross Armstrong Halliday
Aziz Naeem Khan
Original Assignee
Resverlogix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resverlogix Corp filed Critical Resverlogix Corp
Publication of MX2022005029A publication Critical patent/MX2022005029A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
MX2022005029A 2019-11-05 2020-11-04 Metodos de tratamiento y/o prevencion de acontecimientos cardiovasculares adversos graves (mace) con una combinacion de un inhibidor de bromodominio y extraterminal (bet) y un inhibidor de transporte de glucosa dependiente de sodio 2. MX2022005029A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962930860P 2019-11-05 2019-11-05
PCT/IB2020/000912 WO2021090061A1 (en) 2019-11-05 2020-11-04 Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor

Publications (1)

Publication Number Publication Date
MX2022005029A true MX2022005029A (es) 2022-07-12

Family

ID=75849803

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005029A MX2022005029A (es) 2019-11-05 2020-11-04 Metodos de tratamiento y/o prevencion de acontecimientos cardiovasculares adversos graves (mace) con una combinacion de un inhibidor de bromodominio y extraterminal (bet) y un inhibidor de transporte de glucosa dependiente de sodio 2.

Country Status (18)

Country Link
US (1) US12551484B2 (https=)
EP (1) EP4054584B1 (https=)
JP (1) JP7502811B2 (https=)
KR (1) KR102935008B1 (https=)
CN (1) CN114650824A (https=)
AU (1) AU2020377539B2 (https=)
BR (1) BR112022008223A2 (https=)
CA (1) CA3160147A1 (https=)
DK (1) DK4054584T3 (https=)
ES (1) ES3042146T3 (https=)
FI (1) FI4054584T3 (https=)
HU (1) HUE073043T2 (https=)
IL (1) IL292696B1 (https=)
MX (1) MX2022005029A (https=)
PL (1) PL4054584T3 (https=)
PT (1) PT4054584T (https=)
TW (1) TWI867086B (https=)
WO (1) WO2021090061A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114650824A (zh) 2019-11-05 2022-06-21 雷斯韦洛吉克斯公司 用bet溴结构域抑制剂和钠依赖性葡萄糖转运蛋白2抑制剂的组合治疗和/或预防主要不良心血管事件(mace)的方法
US20230398137A1 (en) * 2020-10-30 2023-12-14 Resverlogix Corp. Methods for lowering hba1c level with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
US20220370485A1 (en) * 2021-01-14 2022-11-24 Lexicon Pharmaceuticals, Inc. Compounds and methods for treating or preventing cardiovascular diseases and conditions

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410109B2 (en) 2005-07-29 2013-04-02 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
SI2346837T1 (sl) 2008-06-26 2015-05-29 Resverlogix Corporation Postopki pripravljanja kinazolinonskih derivatov
KR101913109B1 (ko) 2009-03-18 2018-10-31 리스버로직스 코퍼레이션 신규한 소염제
MX2011009852A (es) 2009-03-27 2011-09-29 Bristol Myers Squibb Co Metodos para prevenir episodios cardiovasculares adversos mayores con inhibidores de dipeptidil peptidasa iv.
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
JP2012528170A (ja) 2009-05-27 2012-11-12 ブリストル−マイヤーズ スクイブ カンパニー 別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法
CA2851996C (en) 2011-11-01 2020-01-07 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
US20130281398A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
EP4678242A3 (en) 2013-04-18 2026-03-18 Boehringer Ingelheim International GmbH Pharmaceutical composition, methods for treating and uses thereof
HK1219434A1 (zh) * 2013-08-21 2017-04-07 Resverlogix Corp. 用於加速斑块消退的组合物和治疗方法
AU2014310371A1 (en) 2013-08-21 2016-03-10 Resverlogix Corp. Compositions and therapeutic methods for accelerated plaque regression
TW201625605A (zh) * 2014-04-04 2016-07-16 賽諾菲公司 用於治療糖尿病、肥胖、血脂異常及相關病症之作為ｇｐｒ１１９調節劑的經取代之稠合雜環類
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
EP3355922A2 (en) * 2015-10-02 2018-08-08 Dana Farber Cancer Institute, Inc. Combination therapy of bromodomain inhibitors and checkpoint blockade
EP3553058A1 (en) 2016-12-09 2019-10-16 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of bromodomain protein inhibitor drug, preparation method and use thereof
US11419883B2 (en) 2017-05-05 2022-08-23 The Regents Of The University Of California Inhibiting senescent processes in beta cells for the prevention of type 1 diabetes
CN114650824A (zh) 2019-11-05 2022-06-21 雷斯韦洛吉克斯公司 用bet溴结构域抑制剂和钠依赖性葡萄糖转运蛋白2抑制剂的组合治疗和/或预防主要不良心血管事件(mace)的方法
JP7763761B2 (ja) 2020-01-08 2025-11-04 レスバーロジックス コーポレイション Ｂｅｔブロモドメイン阻害剤およびジペプチジルペプチダーゼ４阻害剤の組合せによる主要有害心血管イベント（ｍａｃｅ）の治療方法および／または予防方法
US20230398137A1 (en) * 2020-10-30 2023-12-14 Resverlogix Corp. Methods for lowering hba1c level with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor
CA3197706A1 (en) 2020-10-30 2022-05-05 Resverlogix Corp. Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor

Also Published As

Publication number Publication date
KR20220098757A (ko) 2022-07-12
IL292696B1 (en) 2026-01-01
EP4054584B1 (en) 2025-07-09
IL292696A (en) 2022-07-01
US20220370452A1 (en) 2022-11-24
BR112022008223A2 (pt) 2022-09-06
HUE073043T2 (hu) 2025-12-28
TW202131924A (zh) 2021-09-01
AU2020377539A1 (en) 2022-05-19
CN114650824A (zh) 2022-06-21
ES3042146T3 (en) 2025-11-18
DK4054584T3 (en) 2025-09-01
FI4054584T3 (fi) 2025-08-22
CA3160147A1 (en) 2021-05-14
TWI867086B (zh) 2024-12-21
EP4054584A4 (en) 2023-11-08
EP4054584A1 (en) 2022-09-14
KR102935008B1 (ko) 2026-03-09
PT4054584T (pt) 2025-07-16
AU2020377539B2 (en) 2025-05-29
JP2023500685A (ja) 2023-01-10
PL4054584T3 (pl) 2025-11-03
WO2021090061A1 (en) 2021-05-14
US12551484B2 (en) 2026-02-17
JP7502811B2 (ja) 2024-06-19

Similar Documents

Publication Publication Date Title
PH12020550107A1 (en) Chromane monobactam compounds for the treatment of bacterial infections
MX2022005029A (es) Metodos de tratamiento y/o prevencion de acontecimientos cardiovasculares adversos graves (mace) con una combinacion de un inhibidor de bromodominio y extraterminal (bet) y un inhibidor de transporte de glucosa dependiente de sodio 2.
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
WO2020033838A3 (en) Treatment of egfr-mutant cancer
PH12023550160A1 (en) Combinations for the Treatment of Cancer
PH12021552513A1 (en) Pyrrole compounds
EP4353317A3 (en) Ret inhibitor for use in treating cancer having a ret alteration
MX2023013225A (es) Inhibidores de la cinasa 4 similar a polo.
SG11201908234WA (en) Pharmaceutical composition comprising compound capable of penetrating blood-brain barrier as effective ingredient for preventing or treating brain cancer
ZA202406651B (en) Pharmaceutical composition comprising anti-ctla4-anti-pd-1 bispecific antibody and chiauranib
TW200639159A (en) Treatment of pain
MX2022003845A (es) Tratamientos cognitivos medicinales.
MX2020007817A (es) Prevención y tratamiento del trastorno del sueño.
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
MX2023014898A (es) Terapia combinada anti-vhc ventajosa.
EA201290827A1 (ru) Офтальмологический раствор для лечения глазной инфекции, содержащий левофлоксацин или его соль или сольват этих соединений, способ лечения глазной инфекции, левофлоксацин или его соль или сольват этих соединений и их применение
WO2020250182A3 (ko) 지페노사이드 화합물을 유효성분으로 포함하는 퇴행성 신경질환 치료용 조성물
EA202193211A1 (ru) Лечение синуклеопатий
MX2023009620A (es) Metodos terapeuticos.
WO2019241641A3 (en) Cancer treatment methods
MX2023004671A (es) Metodos para mejorar la funcion renal con una combinacion de un inhibidor del bromodominio y dominio extraterminal (bet) y un inhibidor del transporte de la glucosa dependiente del sodio 2.
PH12020551620A1 (en) Compositions for preventing or treating dry eye
WO2021015294A3 (en) Combination therapy for cancer treatment
EA202191415A1 (ru) Комбинированная терапия, включающая ингибитор krasg12c и одно или несколько дополнительных фармацевтически активных средств, для лечения видов рака
MX2021011469A (es) Combinacion de lisina(s) y antibiotico(s) para tratar o prevenir endocarditis infecciosa debida a bacterias gram-positivas.